2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-176791
    CDK12-Cyclin K Ligand-Linker Conjugates 1
    		Inhibitor
    CDK12-Cyclin K Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CDK12-Cyclin K (HY-176790) and a PROTAC linker (HY-W244922), which recruits E3 ligases. CDK12-Cyclin K Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC PP-C8 (HY-144691).
    CDK12-Cyclin K Ligand-Linker Conjugates 1
  • HY-178499
    CDK9-IN-44
    		Inhibitor
    CDK9-IN-44 (Compound 7) is a selective CDK9 inhibitor (IC50=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders.
    CDK9-IN-44
  • HY-180157
    CDK2-IN-51
    		Inhibitor
    CDK2-IN-51 is a pyrazolopyridine derivative, a CDK2 inhibitor with an IC50 of 23.47 nM. CDK2-IN-51 does not have a pro-apoptotic effect and had no significant effect on CDK2 protein expression. CDK2-IN-51 reduces expression of DNA replication factors (Polα, MCM7, ORC2, and ORC4) and pre-G1 cell cycle arrest. CDK2-IN-51 can be used for the research of colorectal cancer.
    CDK2-IN-51
  • HY-113670
    CLK1/2-IN-2
    		Inhibitor 99.31%
    CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities[1].
    CLK1/2-IN-2
  • HY-RS02367
    Cdk16 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk16 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk16 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk16 Mouse Pre-designed siRNA Set A
  • HY-175638
    Carbonic anhydrase-IN-35
    		Inhibitor
    Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer.
    Carbonic anhydrase-IN-35
  • HY-E70657
    CDK10/CycQ Recombinant Human Active Protein Kinase
    CDK10/CycQ Recombinant Human Active Protein Kinase is a cyclin-dependent kinase, which is important for neural development and can act as a tumour suppressor.
    CDK10/CycQ Recombinant Human Active Protein Kinase
  • HY-170507
    CDK-IN-16
    		Inhibitor
    CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC50 of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC50 of CDK-IN-16 against the AGS cell line is 3.5 μM.
    CDK-IN-16
  • HY-E70691
    CLK1 Recombinant Human Active Protein Kinase
    CLK1 is one of the dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 Recombinant Human Active Protein Kinase is a recombinant CLK1 protein that can be used to study CLK1-related functions.
    CLK1 Recombinant Human Active Protein Kinase
  • HY-149870
    PROTAC CDK9 degrader-8
    		Inhibitor
    PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC50 value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer.
    PROTAC CDK9 degrader-8
  • HY-RS02373
    Cdk19 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cdk19 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk19 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk19 Rat Pre-designed siRNA Set A
  • HY-180278
    PROTAC CDK6 ligand 2
    		Inhibitor
    PROTAC CDK6 ligand 2 is a ligand for target CDK6 protein for PROTAC. PROTAC CDK6 ligand 2 can be used for the synthesis of PROTAC CDK6 Degrader 1 (HY-180277).
    PROTAC CDK6 ligand 2
  • HY-RS02362
    CDK14 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK14 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK14 Human Pre-designed siRNA Set A
  • HY-181405
    SR-5037
    		Inhibitor 99.58%
    SR-5037 is an orally active CDK12 (IC50 = 31 nM)/CDK13 inhibitor and CycK (DC50 = 30 nM;
    Dmax > 98%) molecular glue degrader. SR-5037 inhibits the enzymatic activity of CDK12/CycK and CDK13/CycK complexes. SR-5037 promotes the recruitment of DDB1 to the CDK12/CycK complex, thereby triggering proteasome-mediated CycK degradation. SR-5037 degrades active CycK in mouse models of triple-negative breast cancer. SR-5037 can be used in the research of cancers such as triple-negative breast cancer.
    SR-5037
  • HY-147602
    CDK7-IN-17
    		Inhibitor
    CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1).
    CDK7-IN-17
  • HY-179151
    CDK4/6-IN-26
    		Inhibitor
    CDK4/6-IN-26 is a carbamate derivative that targets CDK4/CDK6. CDK4/6-IN-26 reduces CDK4/CDK6 levels, resulting in cell cycle arrest in the G0/G1 phase and in the S phase. CDK4/6-IN-26 exhibits high potency against SW480 cells (IC50 = 6.3 μM). CDK4/6-IN-26 affects ROS levels by increasing the expression of SOD2/MnSOD. CDK4/6-IN-26 establishes several interactions with the amino acids of the CDK6 active site. CDK4/6-IN-26 can be used for the research of colorectal cancer.
    CDK4/6-IN-26
  • HY-178516
    PROTAC CDK4/6/9 degrader 2
    		Degrader
    PROTAC CDK4/6/9 degrader 2 (Compound P4) is a CDK4/6/9 PROTAC prodrug with oral activity and low toxicity. PROTAC CDK4/6/9 degrader 2 can significantly inhibit tumor growth and suppress tumor lung metastasis. PROTAC CDK4/6/9 degrader 2 can be used in the research of cancer such as breast cancer. (Pink: CDK4/6/9 Ligand (HY-168440); Blue: CRBN Ligand (HY-178517); Black: Linker (HY-178512))
    PROTAC CDK4/6/9 degrader 2
  • HY-181140
    UNPD139734
    		Inhibitor
    UNPD139734 is a CDK-1 inhibitor and PARP-1 inhibitor that forms stable complexes with each target protein. UNPD139734 serves as a lead compound for structural optimization to develop dual-target anticancer agents targeting CDK-1 and PARP-1. UNPD139734 can be used for the research of breast cancer.
    UNPD139734
  • HY-P5428
    Cdc2 kinase substrate
    		Substrate
    Cdc2 kinase substrate is a biological active peptide. (The native peptide HATPPKKKRK is a substrate for cyclin-dependent protein kinase 1 (CDC2; CDK1).)
    Cdc2 kinase substrate
  • HY-182312
    CTX-439
    		Inhibitor
    CTX-439 is an orally active, ATP-competitive small-molecule inhibitor of CDK12 and CDK13, with an IC50 of 3.1 nM and a Kd of 0.38 nM against CDK12, and an IC50 of 9.2 nM against CDK13. CTX-439 induces DNA damage and apoptosis in tumor cells. CTX-439 is applicable for the research of breast cancer and ovarian cancer.
    CTX-439
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.